Hack My Age : Menopause Upgrade Hormone Therapy and Bone Health in Menopause, What the Research Actually Shows - Zora Benhamou
4 snips
Mar 16, 2026 An engaging deep dive into how estrogen controls bone remodeling and why bone loss often accelerates around perimenopause. A clear look at what clinical research says about hormone therapy and fracture risk. Practical discussion of timing, estradiol targets, and which people may gain the most benefit. Emphasis on HRT as one part of a broader bone health plan.
AI Snips
Chapters
Transcript
Episode notes
Estrogen Is The Key Regulator Of Bone Remodeling
- Estrogen controls bone remodeling by suppressing osteoclasts and supporting osteoblasts, so loss of estrogen speeds bone breakdown.
- Menopause shifts this balance so resorption outpaces formation, causing rapid bone loss especially early on.
Most Bone Loss Happens Around Menopause
- Bone loss accelerates around perimenopause and peaks in the first five years after menopause, accounting for roughly 10–20% of lifetime bone decline.
- The first 5–10 years post‑menopause represent about half of lifetime bone loss, making timing critical.
Consider HRT For Bone Fracture Prevention
- Hundreds of randomized trials and >20 meta-analyses show hormone therapy reduces bone loss, preserves BMD, and lowers fracture risk.
- Major menopausal societies endorse HRT as a preventive measure for bone health during menopause.